Philogen is a Swiss-Italian integrated biotechnology company founded in 1996, with the mission to develop innovative biopharmaceuticals for the treatment of angiogenesis-related disorders. Angiogenesis, i.e. the formation of new blood vessels, is a characteristic feature of many severe pathologies such as cancer, rheumatoid arthritis and age-related macular degeneration.
The company has been a pioneer in the isolation, engineering and clinical development of lead products capable of targeting angiogenesis in-vivo and has been the first in the world to demonstrate that human monoclonal antibodies, specific for a marker of angiogenesis, can efficiently and selectively target the tumor neo-vasculature both in animal models and in cancer patients.
At present, Philogen has various armed antibody product in clinical development for the treatment of cancer and of chronic disease. One product has started Phase III clinical trial (Daromun), while an application for Phase III clinical trial has been submitted for another product (Fibromun).
Our Zurich-based daughter company Philochem isolates the most promising lead candidates, while in Siena (Italy) the pharmaceuticals are optimized, produced according to GMP standards and investigated in clinical trials.
Philogen generates revenue from a diversified range of activities, has signed agreements with major pharmaceutical companies and owns a diversified portfolio of international patents